TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES最新文献

筛选

英文中文

A Pooled Analysis of Mortality in Patients with COPD Receiving Triple Therapy versus Dual Bronchodilation 慢性阻塞性肺病患者接受三联治疗与双重支气管扩张的死亡率汇总分析

TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES Pub Date : 2021-05-19 DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2251

M. Miravitlles, P. Calverley, K. Verhamme, M. Dreher, V. Bayer, A. Gardev, A. Hoz, J. Wedzicha, D. Price

{"title":"A Pooled Analysis of Mortality in Patients with COPD Receiving Triple Therapy versus Dual Bronchodilation","authors":"M. Miravitlles, P. Calverley, K. Verhamme, M. Dreher, V. Bayer, A. Gardev, A. Hoz, J. Wedzicha, D. Price","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2251","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2251","url":null,"abstract":"Introduction : A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to-severe COPD and predominantly lower exacerbation risk. Methods : Patients who received either LAMA+LABA+ICS (n=11,891) or LAMA+LABA (n=3,156) were pooled from phase 3/4 randomized controlled trials (TONADO 1/2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR). Analysis was on-treatment and censored at 52 weeks. Propensity score (PS)-matched cohorts (covariates: age, sex, Conclusions : This pooled analysis showed no differences in mortality between LAMA+LABA and LAMA+LABA+ICS in patients with moderate-to-severe COPD and predominantly lower exacerbation risk.","PeriodicalId":169302,"journal":{"name":"TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130382972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Outcome of Surgical and Endoscopic Lung Volume Reduction with Valves in Patients with Severe Lung Emphysema: Preliminary Results from the National Lung Emphysema Registry (LE-R) in Germany 严重肺气肿患者手术和内镜下肺减容加瓣膜治疗的结果:来自德国国家肺气肿登记处(LE-R)的初步结果

TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES Pub Date : 2021-05-01 DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2261

P. Lenga, C. Grah, C. Ruwwe-Glösenkamp, J. Saccomanno, S. Eggeling, J. Pfannschmidt, S. Gläser, S. Kurz, G. Lesschber, J. Rückert, B. Schmidt, P. Schneider, R. A. Gebhardt, A. Gebhardt, B. Becke, O. Schega, A. Holland, A. Kirschbaum, S. Eisenmann, M. Krüger, R. Hübner

引用次数: 1